Physician profile
Dutsi A Behm
NPI 1982780078
$6,002.66
in general payments reported to CMS, 2019-2025
32 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $441 · 2021: $1,102 · 2022: $1,167 · 2023: $1,044 · 2024: $854 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.87 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.52 | 2019-2025 | Linzess, Viberzi, Creon |
| Lilly USA, LLC | $927.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $785.16 | 2019-2023 | |
| Amgen INC. | $750.22 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $348.30 | 2019-2025 | Wegovy |
| Abbott Laboratories | $203.34 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $201.68 | 2021-2024 | |
| Amarin Pharma, INC. | $162.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.12 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $152.43 | 2021-2022 | |
| Astellas Pharma US INC | $147.25 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $120.92 | 2019-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $97.45 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $82.73 | 2019-2021 | |
| Pfizer INC. | $64.94 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $62.39 | 2020-2024 | Nexletol |
| Vivus LLC | $60.75 | 2019 | |
| Aimmune Therapeutics, INC. | $59.10 | 2024-2025 | Vowst |
| Allergan, INC. | $55.29 | 2019 | |
| Ironwood Pharmaceuticals, INC | $52.16 | 2021-2023 | Linzess |
| Kowa Pharmaceuticals America, INC. | $41.70 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.31 | 2020 | |
| Glaxosmithkline, LLC. | $36.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.31 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.44 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $20.31 | 2023 | Eliquis |
| Alexion Pharmaceuticals, INC. | $19.95 | 2021 | |
| Horizon Therapeutics Plc | $19.58 | 2021 | |
| Dexcom, INC. | $18.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.02 | 2024 | Nuzyra |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dutsi Behm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.